These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22153922)

  • 1. The association between sunshine duration and paroxetine response time in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Kaneda A; Kaneko S
    J Affect Disord; 2012 Feb; 136(3):1067-71. PubMed ID: 22153922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of personality factors on paroxetine response time in patients with major depression.
    Kaneda A; Yasui-Furukori N; Nakagami T; Sato Y; Kaneko S
    J Affect Disord; 2011 Dec; 135(1-3):321-5. PubMed ID: 21784533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
    Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
    PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment.
    Tomita T; Sato Y; Nakagami T; Tsuchimine S; Kaneda A; Kaneko S; Nakamura K; Yasui-Furukori N
    Clin Neuropharmacol; 2015; 38(1):6-10. PubMed ID: 25580920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
    Aberg-Wistedt A; Agren H; Ekselius L; Bengtsson F; Akerblad AC
    J Clin Psychopharmacol; 2000 Dec; 20(6):645-52. PubMed ID: 11106136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personality change during depression treatment: a placebo-controlled trial.
    Tang TZ; DeRubeis RJ; Hollon SD; Amsterdam J; Shelton R; Schalet B
    Arch Gen Psychiatry; 2009 Dec; 66(12):1322-30. PubMed ID: 19996037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM; Gao KR; Yu H; Shen YF; Li HF
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.
    Ruhé HG; Koster M; Booij J; van Herk M; Veltman DJ; Schene AH
    Psychiatry Res; 2014 Feb; 221(2):155-61. PubMed ID: 24406081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.
    Bozina N; Peles AM; Sagud M; Bilusic H; Jakovljevic M
    World J Biol Psychiatry; 2008; 9(3):190-7. PubMed ID: 17853254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders.
    Yasui-Furukori N; Nakagami T; Kaneda A; Inoue Y; Suzuki A; Otani K; Kaneko S
    Hum Psychopharmacol; 2011 Dec; 26(8):602-8. PubMed ID: 22102561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder.
    Tomita T; Sato Y; Nakagami T; Tsuchimine S; Kaneda A; Kaneko S; Nakamura K; Yasui-Furukori N
    Clin Neuropharmacol; 2016; 39(3):135-9. PubMed ID: 27171569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder.
    Guan X; Dong ZQ; Hao YN; Shen XL; Xie QL; Chen JM
    Hum Psychopharmacol; 2022 Nov; 37(6):e2855. PubMed ID: 36194639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
    Bogetto F; Bellino S; Revello RB; Patria L
    CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the Temperament and Character Inventory dimensions after paroxetine treatment in patients with major depressive disorder.
    Tomita T; Kaneda A; Nakagami T; Kaneko S; Yasui-Furukori N
    Hum Psychopharmacol; 2015 Sep; 30(5):334-40. PubMed ID: 25845342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.